Week In Review: Three China In-Licensing Deals Add Up To $662 Million

Simcere Pharma of Nanjing announced a $292 million agreement to develop a proposed Kazia Therapeutics treatment for glioma in Greater China. Qihan Biotechnology raised $67 million in a Series A++ round to advance its portfolio of cell therapies.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.